Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27403589 | 0.78 | CYP2D6 (0.65) | DRD2DRD3HTR1ACYP2D6SLC6A2 | |
| SCHEMBL2599485 | 0.78 | CYP2D6 (0.65) | DRD2DRD3HTR1ACYP2D6SLC6A2 | |
| Hydrochloric Acid SCHEMBL2599502 | 0.77 | CYP2D6 (0.63) | DRD2DRD3HTR1ACYP2D6SLC6A2 | |
| SCHEMBL1626963 | 0.73 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL4536932 | 0.73 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL8538844 | 0.73 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL357358 | 0.73 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL319782 | 0.72 | DRD2 (0.63) | DRD2DRD3HTR1A | |
| Hydrochloric Acid SCHEMBL1711121 | 0.72 | DRD2 (0.63) | DRD2DRD3HTR1A | |
| Ammonia Solution, Strong SCHEMBL27880976 | 0.72 | DRD2 (0.63) | DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | DRD2 3896/4885DRD3 3359/4885HTR1A 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.